Maze Therapeutics, Inc. - MAZE

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Aug 14, 2026 SCHEDULE 13G/A Paradigm BioCapital Advisors LP 0.0% 0 View
Aug 14, 2026 SCHEDULE 13G/A Paradigm BioCapital Advisors GP LLC 0.0% 0 View
Aug 14, 2026 SCHEDULE 13G/A Senai Asefaw, M.D. 0.0% 0 View
Aug 14, 2026 SCHEDULE 13G/A Paradigm BioCapital International Fund Ltd. 0.0% 0 View
Jul 29, 2026 SCHEDULE 13G BlackRock, Inc. 5.4% 2,978,114 View
May 15, 2026 SCHEDULE 13G/A JANUS HENDERSON GROUP PLC 5.8% 2,858,876 View
Apr 01, 2026 SCHEDULE 13G Paradigm BioCapital Advisors LP 6.1% 3,051,087 View
Apr 01, 2026 SCHEDULE 13G Paradigm BioCapital Advisors GP LLC 6.1% 3,051,087 View
Apr 01, 2026 SCHEDULE 13G Senai Asefaw, M.D. 6.1% 3,051,087 View
Apr 01, 2026 SCHEDULE 13G Paradigm BioCapital International Fund Ltd. 5.4% 2,688,520 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.